Aarhus University Seal / Aarhus Universitets segl

Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • FBE Klinisk Biokemisk Syd, Aalborg Sygehus
  • The Department of Infectious Diseases
Recently, entecavir was introduced as a potent drug against hepatitis B virus infection. Initially, it was suggested not to have any effect on human immunodeficiency virus (HIV) infection. This guideline was revised in 2007 because of a report showing that the M184V mutation was selected in an hepatitis B virus and HIV-coinfected patient previously treated with lamivudine. Our investigation revealed findings similar to those preveiously reported but in an antiretroviral therapy-naive patient coinfected with HIV and hepatitis B virus. After 26 weeks of entecavir therapy, the M184V mutation dominated the plasma viral population. Thus, entecavir should only be used for coinfected patients who simultaneously receive suppressive therapy against HIV infection.
Original languageEnglish
JournalClinical Infectious Diseases
Pages (from-to)e88-91
Publication statusPublished - 2008

    Research areas

  • Aged, Anti-HIV Agents, Guanine, HIV Infections, HIV Reverse Transcriptase, Humans, Male, Mutation, Phylogeny, env Gene Products, Human Immunodeficiency Virus

See relations at Aarhus University Citationformats

ID: 12728358